Sanofi returns to growth as promised, with Dupixent and vaccines leading the turnaround
admin 31st October 2018 Uncategorised 0Having been hurt by competition to its diabetes and cardiovascular franchise, Sanofi CEO Olivier Brandicourt has pledged a return to growth starting from the second half of 2018. Thanks mainly to Dupixent and now-recovered vaccines sales, he kept his word.
read more